Insulin glargine (Abasaglar®)
All Wales Medicines Strategy Group (AWMSG)
Record ID 32015001232
English
Authors' recommendations:
Insulin glargine (Abasaglar®) is recommended as an option for restricted use within NHS Wales for the treatment of diabetes mellitus in adults, adolescents and children aged 2 years and above. Insulin glargine (Abasaglar®) should be prescribed within its licensed indication in accordance with NICE or AWMSG guidance for insulin glargine (Lantus®), the reference product. Insulin glargine (Abasaglar®) is not recommended for use within NHS Wales outside of these circumstances. Insulin glargine (Abasaglar®) should be prescribed by brand name to avoid automatic substitution and therefore help with pharmacovigilance.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.awmsg.org/awmsgonline/app/appraisalinfo/2307
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Wales, United Kingdom
MeSH Terms
- Humans
- Diabetes Mellitus
- Insulin, Long-Acting
- Pharmacovigilance
Contact
Organisation Name:
All Wales Medicines Strategy Group
Contact Address:
All Wales Therapeutics and Toxicology Centre, Academic Centre, University Hospital Llandough, Penlan Road, Penarth, Vale of Glamorgan CF64 2XX
Contact Name:
AWTTC@wales.nhs.uk
Contact Email:
AWTTC@wales.nhs.uk
Copyright:
AWTTC
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.